复合均衡营养粉在耐多药结核病患者抗结核治疗中的应用效果分析

doi:10.19982/j.issn.1000-6621.20250350

中国防痨杂志 ›› 2026, Vol. 48 ›› Issue (3): 349-355.doi: 10.19982/j.issn.1000-6621.20250350

复合均衡营养粉在耐多药结核病患者抗结核治疗中的应用效果分析

韦柳迎¹, 吴幸幸¹, 黄连飘¹, 曾春梅¹, 赵春艳², 宋畅², 聂文娟³, 裴洁¹, 韦小英¹, 黄爱春¹, 朱庆东¹, 谢周华¹, 黄献珍¹()

¹南宁市第四人民医院结核科,南宁 530023
²广西医科大学,南宁 530021
³首都医科大学附属北京胸科医院结核一科,北京 101149

收稿日期:2025-08-28 出版日期:2026-03-10 发布日期:2026-03-06
通信作者: 黄献珍 E-mail:170095583@qq.com
基金资助:
南宁市科学研究与技术开发计划项目(20213025-3);广西重点研发计划项目(桂科AB25069097);广西壮族自治区卫生健康委员会自筹经费科研课题(Z20210932)

Analysis of the application effect of compound balanced nutrition powder in anti-tuberculosis treatment on multidrug-resistant tuberculosis patients

Wei Liuying¹, Wu Xingxing¹, Huang Lianpiao¹, Zeng Chunmei¹, Zhao Chunyan², Song Chang², Nie Wenjuan³, Pei Jie¹, Wei Xiaoying¹, Huang Aichun¹, Zhu Qingdong¹, Xie Zhouhua¹, Huang Xianzhen¹()

¹Department of Tuberculosis, Nanning Fourth People’s Hospital, Nanning 530023, China
²Guangxi Medical University, Nanning 530021, China
³Department of Tuberculosis 1, Capital Medical University, Beijing Chest Hospital, Beijing 101149, China

Received:2025-08-28 Online:2026-03-10 Published:2026-03-06
Contact: Huang Xianzhen E-mail:170095583@qq.com
Supported by:
Nanning Science Research and Technology Development Program(20213025-3);Guangxi Key Research and Development Program(Guike AB25069097);Self-funded Research Project of Guangxi Zhuang Autonomous Region Health Commission(Z20210932)

摘要/Abstract

摘要：

目的: 探讨复合均衡营养粉在耐多药结核病(MDR-TB)患者抗结核治疗中的应用效果。方法: 将2021年1月1日至2023年6月30日在南宁市第四人民医院收治的MDR-TB患者,应用NRS 2002评分简表进行营养风险筛查,评分≥3分的204例MDR-TB患者,按入组时间顺序,Excel RAND 随机排序后,奇数号102例为干预组,偶数号102例为对照组。排除失访或放弃治疗等,共有干预组患者98例,对照组患者92例纳入研究。对照组在营养科医师再次进行营养风险筛查后,进行营养评定、诊断,根据患者营养不良程度计算每日摄入总热量,指导患者饮食。干预组在此基础上,服用复合均衡营养粉。两组患者的营养干预与抗结核治疗同时进行。在1、2、3、6个月末4个关键节点收集并对比各个时段的相关指标的变化,以及NRS 2002营养风险筛查评分结果,评价复合均衡营养粉对MDR-TB 患者营养治疗的效果。结果: 1个月末,干预组的白蛋白为(39.85±8.05)g/L,对照组为(37.22±7.42)g/L,两组比较差异有统计学意义(t=-2.337,P=0.021)。6个月末,干预组的总蛋白为(70.14±10.28)g/L,对照组为(72.87±7.43)g/L,两组比较差异有统计学意义(t=2.090,P=0.038)。干预组痰涂片与培养阴性率均高于对照组:1个月末分别为85.71%(84/98)和 75.00%(69/92)、81.63% (80/98)和 70.65%(65/92),两组比较差异均无统计学意义 (χ²值分别为3.474和3.165, P值分别为0.062和0.075);2个月末为96.94% (95/98)和 92.39%(85/92)、91.84%(90/98) 和 88.04%(81/92),但差异均无统计学意义 (χ²值分别为1.968和0.759, P值分别为0.161和0.384);3个月末均为98.98%(97/98),对照组均为98.91%(91/92),干预组略高于对照组,但差异无统计学意义(χ²=0.002, P=0.964)。抗结核治疗疗程结束时,干预组的治愈率为94.90%(93/98),高于对照组的治愈率89.13%(82/92),但差异无统计学意义(χ²=2.171, P=0.141)。结论: 使用复合均衡营养制剂辅助治疗能够改善MDR-TB患者的营养状况和临床指标,并在一定程度上提高了MDR-TB患者痰液病原学阴转率,促进患者康复。

关键词: 结核, 抗多种药物性, 营养支持, 治疗结果, 白蛋白类

Abstract:

Objective: To explore the application effect of compound balanced nutrition powder in the anti-tuberculosis treatment on multidrug-resistant tuberculosis (MDR-TB) patients. Methods: From January 1, 2021 to June 30, 2023, MDR-TB patients admitted and treated to Nanning Fourth People’s Hospital were screened for nutritional risk with the NRS 2002 short form. Among 204 MDR-TB cases scoring ≥3, patient admission order was randomized in Excel (RAND function), 102 cases with odd numbers were assigned to the intervention group, and 102 cases with even numbers were assigned to the control group. After excluding lost-to-follow-up or treatment withdrawal cases, 98 patients in the intervention group and 92 patients in the control group were included in the analysis totally. After re-screening by a clinical nutritionist, controls received individualized nutritional assessment and diagnosis, daily caloric intake calculated and dietary counseling according to their degree of malnutrition. The intervention group received the same care plus a compound balanced nutrition powder. Nutritional intervention and anti-tuberculosis therapy proceeded concurrently in both groups. Relevant indicators and NRS 2002 scores were collected at four key time-points—1, 2, 3 and 6 months—to evaluate the effectiveness of the nutritional supplement in MDR-TB patients. Results: At 1 month, average serum albumin in the intervention group was (39.85±8.05) g/L vs. (37.22±7.42) g/L in controls, a difference that was statistically significant (t=-2.337, P=0.021). By 6 months, average total protein was 70.14±10.28 g/L in the intervention group and 72.87±7.43 g/L in controls; this difference was also significant (t=2.090, P=0.038). Sputum-smear and culture conversion rates consistently favored the intervention group: at 1 month 85.71% (84/98) vs. 75.00% (69/92) and 81.63% (80/98) vs. 70.65% (65/92), respectively (χ²=3.474,P=0.062;χ²=3.165, P=0.075); at 2 months 96.94% (95/98) vs. 92.39% (85/92) and 91.84% (90/98) vs. 88.04% (81/92)(χ²=1.968,P=0.161;χ²=0.759, P=0.384); and at 3 months both rates were 98.98% (97/98) for interventions group vs. 98.91% (91/92) for controls (χ²=0.002, P=0.964). At treatment completion, the care rate was 94.90% (93/98) in the intervention group, higher than the 89.13% (82/92) achieved by controls (χ²=2.171, P=0.141). Conclusion: The use of compound balanced nutrition powder as an adjuvant treatment can improve the nutritional status and clinical indicators of MDR-TB patients and to some extent increase the sputum conversion rate of MDR-TB patients, promoting their recovery.

Key words: Tuberculosis, multidrug-resistant, Nutritional support, Treatment outcome, Albumins

中图分类号:

R521
R459.3

韦柳迎, 吴幸幸, 黄连飘, 曾春梅, 赵春艳, 宋畅, 聂文娟, 裴洁, 韦小英, 黄爱春, 朱庆东, 谢周华, 黄献珍. 复合均衡营养粉在耐多药结核病患者抗结核治疗中的应用效果分析[J]. 中国防痨杂志, 2026, 48(3): 349-355. doi: 10.19982/j.issn.1000-6621.20250350

Wei Liuying, Wu Xingxing, Huang Lianpiao, Zeng Chunmei, Zhao Chunyan, Song Chang, Nie Wenjuan, Pei Jie, Wei Xiaoying, Huang Aichun, Zhu Qingdong, Xie Zhouhua, Huang Xianzhen. Analysis of the application effect of compound balanced nutrition powder in anti-tuberculosis treatment on multidrug-resistant tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2026, 48(3): 349-355. doi: 10.19982/j.issn.1000-6621.20250350

图/表 6

表1

表2

表3

表4

表5

表6

参考文献 24

[1]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10): 733-749. doi:10.3760/cma.j.issn.1001-0939.2019.10.006.
[2]	胡鑫洋, 高静韬. 世界卫生组织《2024年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(6):500-504. doi:10.19983/j.issn.2096-8493.2024164.
[3]	Ockenga J, Fuhse K, Chatterjee S, et al. Tuberculosis and malnutrition: The European perspective. Clin Nutr, 2023, 42(4):486-492. doi:10.1016/j.clnu.2023.01.016. URL pmid: 36857957
[4]	Engoru S, Bajunirwe F, Izudi J. Malnutrition and unsuccessful tuberculosis treatment among people with multi-drug resistant tuberculosis in Uganda: A retrospective analysis. J Clin Tuberc Other Mycobact Dis, 2024, 37: 100477. doi:10.1016/j.jctube.2024.100477.
[5]	Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr, 2003, 22(3):321-336. doi:10.1016/s0261-5614(02)00214-5. URL pmid: 12765673
[6]	Martin SJ, Sabina EP. Malnutrition and Associated Disorders in Tuberculosis and Its Therapy. J Diet Suppl, 2019, 16(5):602-610. doi:10.1080/19390211.2018.1472165. URL pmid: 29958051
[7]	Sinha P, Davis J, Saag L, et al. Undernutrition and Tuberculosis: Public Health Implications. J Infect Dis, 2019, 219(9):1356-1363. doi:10.1093/infdis/jiy675. URL pmid: 30476125
[8]	Ma JJ, Guo YJ, Li Z, et al. Prevalence and prognostic significance of malnutrition risk in patients with pulmonary tuberculosis: A hospital-based cohort study. Front Public Health, 2022, 10:1039661. doi:10.3389/fpubh.2022.1039661.
[9]	Koethe JR, von Reyn CF. Protein-calorie malnutrition, macronutrient supplements, and tuberculosis. Int J Tuberc Lung Dis, 2016, 20(7):857-863. doi:10.5588/ijtld.15.0936. URL pmid: 27287634
[10]	Grobler L, Durao S, Van der Merwe SM, et al. Nutritional supplements for people being treated for active tuberculosis: A technical summary. S Afr Med J, 2017, 108(1):16-18. doi:10.7196/SAMJ.2017.v108i1.12839.
[11]	Jeyakumar SM. Micronutrient Deficiency in Pulmonary Tuberculosis-Perspective on Hepatic Drug Metabolism and Pharmacokinetic Variability of First-line Anti-Tuberculosis Drugs: Special Reference to Fat-soluble Vitamins A, D, & E and Nutri-epigenetics. Drug Metab Lett, 2021, 14(3):166-176. doi:10.2174/1872312814999211130093625. URL pmid: 34847853
[12]	Chasapis CT, Ntoupa PA, Spiliopoulou CA, et al. Recent aspects of the effects of zinc on human health. Archives of toxicology, 2020, 94(5): 1443-1460. doi:10.1007/s00190-020-02702-9. URL pmid: 32394086
[13]	Li J, Wu D, Su Z, et al. Zinc-induced photocrosslinked konjac glucomannan/glycyrrhizic acid hydrogel promotes skin wound healing in diabetic mice through immune regulation. Carbohydr Polym, 2025, 348(Pt A):122780. doi:10.1016/j.carbpol.2024.122780.
[14]	Okoka EM, Kuyebi MA, Oyadiran OT, et al. Effect of Micronutrients on HIV-Related Clinical Outcomes Among Adults Living With HIV on Antiretroviral Therapy: Systematic Review and Meta-analysis. Nutr Rev, 2025, 83(7):e1488-e1503. doi:10.1093/nutrit/nuae171.
[15]	Cintron C, Narasimhan PB, Locks L, et al. Tuberculosis-Learning the Impact of Nutrition (TB LION): protocol for an interventional study to decrease TB risk in household contacts. BMC Infect Dis, 2021, 21(1):1058. doi:10.1186/s12879-021-06734-z. URL pmid: 34641820
[16]	Guo X, Yang Y, Zhang B, et al. Nutrition and clinical manifestations of pulmonary tuberculosis: A cross-sectional study in Shandong province, China. Asia Pac J Clin Nutr, 2022, 31(1):41-48. doi:10.6133/apjcn.202203_31(1).0005. URL pmid: 35357102
[17]	McQuaid CF, Sinha P, Bhargava M, et al. Tuberculosis and nutrition: what gets measured gets managed. Lancet Respir Med, 2023, 11(4):308-310. doi:10.1016/S2213-2600(23)00009-7. URL pmid: 36870352
[18]	Zhang Z, Pereira SL, Luo M, et al. Evaluation of Blood Biomarkers Associated with Risk of Malnutrition in Older Adults: A Systematic Review and Meta-Analysis. Nutrients, 2017, 9(8):829. doi:10.3390/nu9080829.
[19]	Jackson AA. Albumin in nephrotic syndrome and oedematous malnutrition. Paediatr Int Child Health, 2015, 35(2):77-80. doi:10.1179/2046904715Z.000000000249.
[20]	Lee B, Han HS, Yoon YS, et al. Impact of preoperative malnutrition, based on albumin level and body mass index, on operative outcomes in patients with pancreatic head cancer. J Hepatobiliary Pancreat Sci, 2021, 28(12):1069-1075. doi:10.1002/jhbp.858. URL pmid: 33128839
[21]	Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med, 2016, 9:229-255. doi:10.2147/IJGM.S102819. URL pmid: 27486341
[22]	Lim WS, Avery A, Kon OM, et al. Anti-tuberculosis drug-induced liver injury. BMJ, 2023, 27,383:e074866. doi:10.1136/bmj-2023-074866.
[23]	Santos EA, Gonçalves JCS, Fleury MK, et al. Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST. Braz J Infect Dis, 2019, 23(6):381-387. doi:10.1016/j.bjid.2019.09.003. URL pmid: 31697922
[24]	季阿芳, 宋全, 潘韵芝, 等. 清肝益脾胶囊抑制抗结核药物性肝损伤肝细胞铁死亡的机制. 中国医院药学杂志, 2023, 43(13): 1458-1464. doi:10.13286/j.1001-5213.2023.13.08.

组别	性别[例,构成比(%)]		年龄 (岁, $\bar{x}±s$)	并发疾病[例,发生率(%)]
组别	男性	女性	年龄 (岁, $\bar{x}±s$)	高血压	心脏病	脑血管病
干预组(98例)	74(75.51)	24(24.49)	44.70±15.37	7(7.14)	3(3.06)	2(2.04)
对照组(92例)	75(81.52)	17(18.48)	40.72±14.96	4(4.35)	0(0.00)	1(1.09)
统计检验值	χ²=1.013		t=-1.812	χ²=0.68	χ²=2.862	χ²=0.278
P值	0.314		0.072	0.410	0.091	0.598

组别	治疗前	1个月末	2个月末	3个月末	6个月末
干预组	112.69±13.62	121.31±20.23	122.04±24.28	126.15±21.69	128.62±27.56
对照组	115.83±20.72	117.84±24.64	124.10±21.81	124.23±25.37	126.87±21.21
t值	1.223	-1.059	0.614	-0.563	-0.487
P值	0.223	0.291	0.540	0.574	0.627

组别	治疗前	1个月末	2个月末	3个月末	6个月末
干预组	67.89±6.89	69.96±8.08	71.22±8.79	70.79±10.12	70.14±10.28
对照组	69.77±6.74	71.24±8.76	73.03±8.54	71.32±8.73	72.87±7.43
t值	1.892	1.054	1.443	0.381	2.090
P值	0.060	0.293	0.151	0.704	0.038

组别	治疗前	1个月末	2个月末	3个月末	6个月末
干预组	33.35±5.52	39.85±8.05	41.05±6.63	40.71±6.67	42.92±7.50
对照组	34.60±5.88	37.22±7.42	38.94±8.14	39.43±7.11	41.83±6.54
t值	1.505	-2.337	-1.946	-1.276	-1.065
P值	0.134	0.021	0.053	0.190	0.288

组别	治疗前	1个月末	2个月末	3个月末	6个月末
干预组	35.34±5.99	31.58±5.94	32.72±6.60	32.00±6.90	29.95±6.20
对照组	35.68±8.14	34.17±7.22	33.87±7.55	32.71±6.73	31.22±7.48
t值	0.323	1.864	1.120	0.725	1.277
P值	0.747	0.064	0.264	0.469	0.203

复合均衡营养粉在耐多药结核病患者抗结核治疗中的应用效果分析

Analysis of the application effect of compound balanced nutrition powder in anti-tuberculosis treatment on multidrug-resistant tuberculosis patients

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

组别	治疗前	1个月末	2个月末	3个月末	6个月末
干预组	1.22±0.70	1.14±0.73	1.23±0.92	1.22±0.80	1.30±0.92
对照组	1.20±0.55	1.23±0.72	1.36±0.72	1.30±0.56	1.46±0.72
t值	-0.226	0.904	1.072	0.855	1.394
P值	0.821	0.367	0.285	0.393	0.165

[1]	王敬, 荆玮, 李维文, 朱庆东, 逄宇, 初乃惠, 聂文娟. 超疗程应用贝达喹啉对于耐多药/利福平耐药肺结核患者的疗效及安全性临床队列分析[J]. 中国防痨杂志, 2026, 48(3): 313-319.
[2]	热依汗古丽·阿肯, 范琳. 营养不良影响结核病患者治疗转归的相关研究进展[J]. 中国防痨杂志, 2026, 48(1): 153-159.
[3]	田晓梅, 蒋学峰, 杨霞, 沙小兰, 雷娟, 王晓炜, 刘静. 2015—2023年宁夏地区MTB/HIV双重感染者发现及治疗转归分析[J]. 中国防痨杂志, 2026, 48(1): 57-63.
[4]	王福燕, 蒋先徳, 肖婷. 个体化营养管理方案对重症肺炎患者的应用效果及血清蛋白、免疫指标的变化[J]. 中国防痨杂志, 2025, 47(S2): 131-133.
[5]	种玉婷, 黄玉蓉, 罗倩. 呼吸支持联合营养支持在高龄重症肺炎患者中的临床应用[J]. 中国防痨杂志, 2025, 47(S1): 147-150.
[6]	周春燕, 蓝小春, 邱慧, 方玉林. 血糖控制水平对糖尿病并发肺结核患者抗结核治疗效果的影响[J]. 中国防痨杂志, 2025, 47(S1): 160-163.
[7]	邵樟芳, 汪丽君, 丁黎黎. 营养支持联合肺康复治疗在妊娠期肺炎患者中的应用分析[J]. 中国防痨杂志, 2025, 47(S1): 171-174.
[8]	任航空, 孙伟峰, 汪林宝. 外科手术治疗慢性空洞性肺病疗效分析[J]. 中国防痨杂志, 2025, 47(9): 1180-1186.
[9]	阿布都热苏力·吐尔孙, 阿布都克尤木江·阿布力孜, 帕提曼·买买提, 黄陈翠, 沈玲燕, 马依迪丽·尼加提. 基于纵向胸部CT的影像组学深度学习预测肺结核患者疗效的研究[J]. 中国防痨杂志, 2025, 47(8): 1044-1052.
[10]	李玉红, 梅金周, 苏伟, 阮云洲, 刘玉舒, 赵雁林, 刘小秋. 2015—2021年全国65岁及以上老年利福平耐药肺结核患者治疗转归及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 408-415.
[11]	吴璇, 张艳秋, 徐吉英, 孟丹, 孙定勇. 2019—2023年河南省肺结核合并糖尿病患者治疗转归影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 425-431.
[12]	安源, 白云龙, 赵庆龙, 马建军, 姜雪, 潘艳, 高迎, 高智慧. 2018—2022年吉林省肺结核合并糖尿病患者治疗转归情况及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 432-438.
[13]	杨海霞, 张小燕, 黄毅, 黎秋. 活动性肺结核合并胸部肿瘤调强放射治疗的安全性及疗效分析[J]. 中国防痨杂志, 2025, 47(3): 312-321.
[14]	王大福, 马晓雪, 王芸, 李福栋, 饶文, 龚婷婷, 李世军, 李进岚. 2016—2023年贵州省合并糖尿病的肺结核患者就诊延迟及不良结局危险因素分析[J]. 中国防痨杂志, 2025, 47(2): 201-209.
[15]	田飞飞, 李玉红, 李雪, 王嘉, 李涛, 杜昕, 赵雁林, 张慧, 刘小秋. 2019—2023年中国肺结核与糖尿病共病患者治疗转归影响因素分析[J]. 中国防痨杂志, 2025, 47(12): 1547-1555.